Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from SAWAI GROUP HOLDINGS Co., Ltd. ( (JP:4887) ) is now available.
Sawai Group Holdings Co., Ltd. announced a settlement with Asahi Kasei Pharma Corporation regarding a patent infringement lawsuit over the generic drug TERIPARATIDE. Sawai Pharmaceutical agreed to pay 4 billion yen to Asahi Kasei Pharma, which waived further claims. The company is reviewing the financial impact and will update stakeholders if necessary.
The most recent analyst rating on (JP:4887) stock is a Hold with a Yen2023.00 price target. To see the full list of analyst forecasts on SAWAI GROUP HOLDINGS Co., Ltd. stock, see the JP:4887 Stock Forecast page.
More about SAWAI GROUP HOLDINGS Co., Ltd.
Sawai Group Holdings Co., Ltd. operates in the pharmaceutical industry, focusing on the production and sale of generic drugs through its subsidiary, Sawai Pharmaceutical Co., Ltd. The company is listed on the Prime Market of the Tokyo Stock Exchange.
Average Trading Volume: 390,688
Technical Sentiment Signal: Buy
Current Market Cap: Yen190.6B
For an in-depth examination of 4887 stock, go to TipRanks’ Overview page.